ImmunityBio, Inc. IBRX Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue.
The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about ImmunityBio, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, intrinsic value.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ImmunityBio, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, intrinsic value?
- ImmunityBio, Inc. (IBRX) reported share-based compensation arrangement by share-based payment award, options, outstanding, intrinsic value of $77.07M in Q1 2026.
- How has ImmunityBio, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, intrinsic value changed year-over-year?
- ImmunityBio, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, intrinsic value increased by 88489.7% year-over-year, from $87K to $77.07M.
- What is the long-term trend for ImmunityBio, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, intrinsic value?
- Over 5 years (2020 to 2025), ImmunityBio, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, intrinsic value has grown at a -77.5% compound annual growth rate (CAGR), from $29.75M to $17K.